Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has today announced that its Annual Report and Accounts for the period ended 31 December 2019 and the Notice of
Alastair Smith gives a video presentation on their recent announcement – SARS-COV-2 Neutralising Affimer Reagents: Potential for a COVID-19 Affimer Therapy. Avacta Group Plc (LON:AVCT) offers reagents and therapeutics based on Affimer
Avacta Group announced that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also been shown to block the interaction between
Avacta Group plc (LON:AVCT) CEO Alastair Smith joins DirectorsTalk to discuss a distribution agreement with Medusa 19 for its rapid antigen test direct to consumer. Alastair talks us through this latest news, provides
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that it has entered into an exclusive distribution agreement with Medusa19 Limited for direct-to-consumer sales of
Lateral flow assay (LFA) based diagnostic tests are widely used for point of care (POC) and consumer/self-testing, due to the combination of rapid results with cost-effective testing, achievable by non-specialists.
Avacta Group PLC (LON:AVCT) is leveraging the antibody-like properties of Affimers for Therapeutic and Diagnostic applications across multi-billion dollar markets, including testing and treatment for COVID-19, building a differentiated pipeline
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, today announced that several of the Affimer reagents recently generated for development of a point-of-care COVID-19 antigen saliva test have now also
Developing the next generation of biotherapeutics Affimer® technology is a novel class of biotherapeutic based on a naturally occurring human protein called Stefin A. Avacta is building a pipeline of clinically
Avacta Group plc (LON:AVCT), the developer of Affimer® biotherapeutics and reagents, has announced that today it is shipping Affimer reagents for COVID-19 antigen testing to its diagnostic test development partners. The Group
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
